Arix Bioscience PLC (ARIX) Result of Annual General Meeting 24-May-2023 / 07:00 GMT/BST
-----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Result of Annual General Meeting
LONDON, 24 May 2023: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.
Full details of the poll results are set out below and will also be available on the Company's website at: https:// arixbioscience.com/investor-relations/document-library?folder=AGM&year=
VOTES TOTAL % of VOTES
No RESOLUTION VOTES FOR % AGAINST % VOTES ISC WITHHELD
VOTED
To receive the Directors' Report and the
1 accounts of the Company for the year ended 68,931,411 100.00% 3,441 0.00% 68,934,852 53.28% 8,440
31 December 2022
To approve the Directors' Remuneration
2 Report 61,073,950 89.25% 7,358,207 10.75% 68,432,157 52.89% 511,135
To re-elect Peregrine Moncreiffe as a
3 Director 68,099,019 98.79% 834,821 1.21% 68,933,840 53.28% 9,452
To re-elect Maureen O'Connell as a
4 Director 68,894,053 99.94% 42,077 0.06% 68,936,130 53.28% 7,162
5 To re-elect Isaac Kohlberg as a Director 68,900,656 99.98% 17,184 0.02% 68,917,840 53.26% 25,452
6 To re-elect Robert Lyne as a Director 68,902,689 99.95% 31,595 0.05% 68,934,284 53.28% 9,008
7 To elect Dr. Debra Barker as a Director 68,907,528 99.95% 32,248 0.05% 68,939,776 53.28% 3,516
8 To elect Andrew Smith as a Director 68,921,195 99.98% 13,089 0.02% 68,934,284 53.28% 9,008
To appoint BDO LLP as auditors of the
9 Company 68,929,881 99.99% 7,445 0.01% 68,937,326 53.28% 5,966
To authorise the Audit and Risk Committee
10 of the Company to fix the auditor's 68,934,245 100.00% 2,013 0.00% 68,936,258 53.28% 7,034
remuneration
11 To authorise the Directors to allot shares 65,989,256 95.72% 2,950,520 4.28% 68,939,776 53.28% 3,516
Authority to disapply statutory pre-
12 emption rights 62,199,252 90.23% 6,734.680 9.77% 68,933,932 53.28% 9,360
Additional authority to disapply statutory
13 pre- emption rights 62,202,105 90.23% 6,731,827 9.77% 68,933,932 53.28% 9,360
To authorise the Company to purchase its
14 own shares 68,921,128 99.98% 17,177 0.02% 68,938,305 53.28% 4,987
Authority to call a general meeting, other
15 than an annual general meeting, on not 68,145,351 98.85% 792,954 1.15% 68,938,305 53.28% 4,987
less than 14 clear days' notice
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed here: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 25 April 2023, which is available on Arix investor relations website at: https://arixbioscience.com/investor-relations/ document-library?folder=AGM&year=
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
----------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071 Category Code: RAG TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 245808 EQS News ID: 1639987 End of Announcement EQS News Service =------------------------------------------------------------------------------------
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1639987&application_name=news
(END) Dow Jones Newswires
May 24, 2023 02:00 ET (06:00 GMT)
